PATENTS

Recent US human gene therapy patents

Breffni Baggot

Patent #	Subject	Assignee	Inventors	Date
5,703,056	Noninvasive imaging of gene transfer: A method of detecting gene transfer to and expression in a target tissue of a host subject.	Sloan-Kettering Inst. for Cancer Research (New York)	Blasberg RG, Tjuvajev J	12/31/97
5,703,055	Generation of antibodies through lipid-mediated DNA delivery: A method for delivering an isolated polynucleotide to the interior of a cell in a vertebrate.	Wisconsin Alumni Research Found. (Madison, WI), Vical Inc. (San Diego, CA)	Felgner PL, Wolff JA, Rhodes GH, Malone RW, Carson, DA	12/31/97
5,702,384	Apparatus for gene therapy: A pulse voltage is applied to needle cannulas to form a pore in the surface of the human living cell upon application of the pulse voltage. The gene is transferred into the human living cell through the pore.	Olympus Optical Co., Ltd. (Tokyo)	Umeyama K, Ogasawara T, Koda K, Yoshino K, Watanabe K,	12/31/97
5,693,536	Gene therapy with MCC: Detection of the alteration of wild-type MCC genes in tumor tissues, and restoration of function of MCC gene product.	Johns Hopkins Univ. (Baltimore, MD), Univ. of Utah (Salt Lake City, UT), The Cancer Inst. (Tokyo)	Vogelstein B, Kinzler KW, White R, Nakamura Y	12/2/97
5,688,675	In vitro packaging of adeno-associated virus DNA: DNA packaged into AAV particles is not limited by the size constraints characteristic of in vivo packaged AAV particles.	Research Found. of State Univ. of New York (Stony Brook, NY)	Zhou X, Muzyczka N, Ni T, Zolotukhin S	11/18/97
5,686,278	Methods for enhanced retrovirus-mediated gene transfer: Increased efficiency of transduction of hematopoietic cells by retroviruses includes infecting the cells in the presence of fibronectin or fibronectin fragments.	Indiana Univ. Found. (Bloomington, IN)	Williams DA, Patel, VP	11/11/97
5,686,263	Method for enhancing gene expression: Introducing into cell a second nucleic acid sequence (homologous to a first endogenous sequence) and a third nucleic acid sequence that encodes a heterologous gene.	Genentech Inc. (S. San Francisco, CA)	Wurm FM	11/11/97
5,681,735	Transcription control element for increasing gene expression in myoblasts: An enhancer element from the upstream region of human myoD and an enhancer element from the upstream region of a quail qmf1.	Fox Chase Cancer Ctr. (Philadelphia, PA)	Emerson CP, Goldhamer DJ	10/28/97
5,681,562	Lymphokine gene therapy of cancer: Autologous fibroblasts genetically modified to secrete at least one cytokine gene product are used to immunize the patient in a formulation with tumor antigens at a site other than an active tumor site.	Sidney Kimmel Cancer Ctr. (San Diego, CA)	Sobol RE, Gage FH, Royston I, Friedman T, Fakhrai H	10/28/97
5,677,178	Cytopathic viruses for therapy and prophylaxis of neoplasia: Preferential generation of replication phenotype in neoplastic cells results in a preferential killing of the neoplastic cells, either directly or by expression of a cytotoxic gene in cells expressing a viral replication phenotype.	Onyx Pharmaceuticals (Richmond, CA)	McCormick F	10/14/97
5,674,722	Genetic modification of endothelial cells: Transduced endothelial cells that have been engineered to express stably maintained genetic material encoding a polypeptide or protein product.	Somatix Therapy (Alameda, CA), Whitehead Institute (Cambridge, MA), Brigham & Womens Hosp. (Boston, MA), Howard Hughes Med. Inst. (Bethesda, MD), New England Med. Ctr. Hospitals (Boston, MA)	Mulligan RC, Cohen LK, Rafi LF, Birinyi LK, Callow AD, Wilson JM	10/7/97
5,670,488	Adenovirus vector for gene therapy: Adenovirus genome from which one or more of the E4 open reading frames has been deleted, but retaining sufficient E4 sequences to promote virus replication in vitro, and additionally comprising a DNA sequence of interest operably linked to expression control sequences and inserted into said adenoviral genome.	Genzyme Corp. (Framingham, MA)	Gregory RJ, Armentano D, Couture LA, Smith AE	9/23/97
5,665,350	Cell cycle-dependent transplantation and ex vivo gene therapy: Transplantation of quiescent stem cells for transplantation therapy and quiescent transfected stem cells for ex vivo gene therapy.	Univ. of Massachusetts Medical Center (Worcester, MA)	Quesenberry PJ	9/9/97

Compiled by Breffni Baggot, an intellectual property lawyer based in Manchester, CT (info@biotechlawyer.com).